Back to Results
First PageMeta Content
Myelodysplastic syndrome / Syndromes / Acute myeloid leukemia / Eisai / Neutropenia / Decitabine / Anemia / Medicine / Oncology / Health


Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc
Add to Reading List

Open Document

File Size: 66,68 KB

Share Result on Facebook

City

DUBLIN / /

Company

Eisai Inc. / Eisai Co. Ltd / Astex Pharmaceuticals Inc. / Janssen-Cilag International NV / Astex Pharmaceuticals Astex Pharmaceuticals / /

Continent

North America / /

Country

United States / /

Event

FDA Phase / Business Partnership / /

IndustryTerm

pharmaceutical / /

MedicalCondition

uncontrolled infection / petechiae / chronic myelomonocytic leukemia / disease / Acute Myeloid Leukemia DUBLIN / leukopenia / myelodysplastic syndromes / hyperglycemia / refractory anemia / neutropenia / nausea / thrombocytopenia / hepatic dysfunction / fatigue / diarrhea / infection / cough / constipation / infections / acute myeloid leukemia / anemia / /

MedicalTreatment

contraception / /

Organization

European Medicines Agency / U.S. Food and Drug Administration / /

Product

Dacogen / Dacogen® (decitabine) / MDS / Acute Myeloid Leukemia / /

ProvinceOrState

California / /

URL

http /

SocialTag